Trial Profile
A 26-weeks Randomised, Insulin Capped, Placebo-controlled, Double-blind, Parallel Group, Multinational, Multi-centre Trial
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 30 Dec 2021
Price :
$35
*
At a glance
- Drugs Liraglutide (Primary)
- Indications Type 1 diabetes mellitus
- Focus Registrational; Therapeutic Use
- Acronyms ADJUNCT TWO
- Sponsors Novo Nordisk
- 01 Dec 2021 Results of post-hoc analysis of two studies (ADJUNCT ONE and ADJUNCT TWO) assessing 26 weeks of liraglutide treatment in type 1 diabetes (T1D), published in the Diabetes, Obesity and Metabolism.
- 29 Jun 2021 Results of randomized controlled phase 3 trials (ADJUNCT ONE (NCT01836523) and TWO (NCT02098395)), presented at the 81st Annual Scientific Sessions of the American Diabetes Association.
- 16 Sep 2016 Results presented at the 52nd Annual Meeting of the European Association for the Study of Diabetes